Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis.

Baker-Williams AJ, Hashmi F, Budzyński MA, Woodford MR, Gleicher S, Himanen SV, Makedon AM, Friedman D, Cortes S, Namek S, Stetler-Stevenson WG, Bratslavsky G, Bah A, Mollapour M, Sistonen L, Bourboulia D.

Cell Rep. 2019 Aug 13;28(7):1894-1906.e6. doi: 10.1016/j.celrep.2019.07.045.

PMID:
31412254
2.

Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity.

Sánchez-Pozo J, Baker-Williams AJ, Woodford MR, Bullard R, Wei B, Mollapour M, Stetler-Stevenson WG, Bratslavsky G, Bourboulia D.

iScience. 2018 Mar 23;1:87-96. doi: 10.1016/j.isci.2018.02.004. Epub 2018 Mar 23.

3.

Macromolecule-Network Electrostatics Controlling Delivery of the Biotherapeutic Cell Modulator TIMP-2.

Yamada Y, Chowdhury A, Schneider JP, Stetler-Stevenson WG.

Biomacromolecules. 2018 Apr 9;19(4):1285-1293. doi: 10.1021/acs.biomac.8b00107. Epub 2018 Mar 19.

4.

Tissue Inhibitor of Metalloprotease-2 (TIMP-2): Bioprocess Development, Physicochemical, Biochemical, and Biological Characterization of Highly Expressed Recombinant Protein.

Chowdhury A, Brinson R, Wei B, Stetler-Stevenson WG.

Biochemistry. 2017 Dec 12;56(49):6423-6433. doi: 10.1021/acs.biochem.7b00700. Epub 2017 Nov 28.

5.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M.

Cell Rep. 2016 Feb 2;14(4):872-884. doi: 10.1016/j.celrep.2015.12.084. Epub 2016 Jan 21.

6.

The tumor microenvironment: the connective tissue/tumor cell/host organ system that modulates tumor progression.

Stetler-Stevenson WG.

Connect Tissue Res. 2015;56(5):343-4. doi: 10.3109/03008207.2015.1086622. No abstract available.

7.

Isolation and characterization of novel RECK tumor suppressor gene splice variants.

Trombetta-Lima M, Winnischofer SM, Demasi MA, Astorino Filho R, Carreira AC, Wei B, de Assis-Ribas T, Konig MS, Bowman-Colin C, Oba-Shinjo SM, Marie SK, Stetler-Stevenson W, Sogayar MC.

Oncotarget. 2015 Oct 20;6(32):33120-33. doi: 10.18632/oncotarget.5305.

8.

c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2015 Aug 11;12(6):1006-18. doi: 10.1016/j.celrep.2015.07.004. Epub 2015 Jul 30.

9.

Anti-inflammatory and antioxidant properties of Piper species: a perspective from screening to molecular mechanisms.

Kumar S, Malhotra S, Prasad AK, Van der Eycken EV, Bracke ME, Stetler-Stevenson WG, Parmar VS, Ghosh B.

Curr Top Med Chem. 2015;15(9):886-93. Review.

10.

Human cardiac fibroblast extracellular matrix remodeling: dual effects of tissue inhibitor of metalloproteinase-2.

Ngu JM, Teng G, Meijndert HC, Mewhort HE, Turnbull JD, Stetler-Stevenson WG, Fedak PW.

Cardiovasc Pathol. 2014 Nov-Dec;23(6):335-43. doi: 10.1016/j.carpath.2014.06.003. Epub 2014 Jun 21.

11.

Dietary intake of a plant phospholipid/lipid conjugate reduces lung cancer growth and tumor angiogenesis.

Shuman Moss LA, Jensen-Taubman S, Rubinstein D, Viole G, Stetler-Stevenson WG.

Carcinogenesis. 2014 Jul;35(7):1556-63. doi: 10.1093/carcin/bgu039. Epub 2014 Feb 7.

12.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.

Mol Cell. 2014 Jan 23;53(2):317-29. doi: 10.1016/j.molcel.2013.12.007.

13.

Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic.

Stetler-Stevenson WG, Gavil NV.

Connect Tissue Res. 2014 Jan-Feb;55(1):13-9. doi: 10.3109/03008207.2013.867339. Review.

14.

Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment.

Remillard TC, Bratslavsky G, Jensen-Taubman S, Stetler-Stevenson WG, Bourboulia D.

Mol Cell Ther. 2014 Jun 3;2:17. doi: 10.1186/2052-8426-2-17. eCollection 2014. Review.

15.

Novel Phenotypic Fluorescent Three-Dimensional Co-Culture Platforms for Recapitulating Tumor in vivo Progression and for Personalized Therapy.

Fang C, Man YG, Cuttitta F, Stetler-Stevenson W, Salomon D, Mazar A, Kulesza P, Rosen S, Avital I, Stojadinovic A, Jewett A, Jiang B, Mulshine J.

J Cancer. 2013 Dec 1;4(9):755-63. doi: 10.7150/jca.7813. eCollection 2013.

16.

Influence of Stromal Components on Lung Cancer Carcinogenesis.

Shuman Moss LA, Stetler-Stevenson WG.

J Carcinog Mutagen. 2013 Jun 25;13(8). doi: 10.4172/2157-2518.S13-008.

17.

SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.

Fang C, Avis I, Bianco C, Held N, Morris J, Ylaya K, Hewitt SM, Aplin AC, Nicosia RF, Fung LA, Lewis JD, Stetler-Stevenson WG, Salomon DS, Cuttitta F.

Open J Clin Diagn. 2013 Jun;3(2):37-51.

18.

Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.

Adamson A, Ghoreschi K, Rittler M, Chen Q, Sun HW, Vahedi G, Kanno Y, Stetler-Stevenson WG, O'Shea JJ, Laurence A.

PLoS One. 2013;8(3):e59367. doi: 10.1371/journal.pone.0059367. Epub 2013 Mar 26.

19.

An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.

Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG.

Oncogene. 2014 Feb 27;33(9):1198-206. doi: 10.1038/onc.2013.61. Epub 2013 Mar 11.

20.

TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.

Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.

Oncotarget. 2013 Jan;4(1):166-76.

21.

Antagonism of VEGF-A-induced increase in vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway.

Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW.

Blood. 2012 Dec 6;120(24):4892-902. doi: 10.1182/blood-2012-05-428243. Epub 2012 Oct 16.

22.

Matrix metalloproteinases: changing roles in tumor progression and metastasis.

Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.

Am J Pathol. 2012 Dec;181(6):1895-9. doi: 10.1016/j.ajpath.2012.08.044. Epub 2012 Oct 12. Review.

23.

Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.

Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.

Cell Cycle. 2012 Oct 1;11(19):3649-55. doi: 10.4161/cc.21926. Epub 2012 Aug 30.

24.

TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis.

Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG.

J Immunother. 2012 Jul;35(6):502-12. doi: 10.1097/CJI.0b013e3182619c8e.

25.

TIMP-2: An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties.

Bourboulia D, Jensen-Taubman S, Stetler-Stevenson WG.

Treat Strategies Hematol. 2012;2(1):31-35. No abstract available.

26.

Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.

Gonçalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM, Gerlach RF.

J Biotechnol. 2012 Jan;157(1):20-4. doi: 10.1016/j.jbiotec.2011.09.030. Epub 2011 Oct 5.

27.

Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG.

Am J Pathol. 2011 Nov;179(5):2589-600. doi: 10.1016/j.ajpath.2011.07.035. Epub 2011 Sep 18.

28.

An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.

Seo DW, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG.

Peptides. 2011 Sep;32(9):1840-8. doi: 10.1016/j.peptides.2011.08.010. Epub 2011 Aug 16.

29.

Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.

Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, Stetler-Stevenson WG, Bewley CA, Khan J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7337-40. doi: 10.1016/j.bmcl.2010.10.064. Epub 2010 Oct 21.

30.

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Bourboulia D, Stetler-Stevenson WG.

Semin Cancer Biol. 2010 Jun;20(3):161-8. doi: 10.1016/j.semcancer.2010.05.002. Epub 2010 May 12. Review.

31.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

32.

TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells.

Lee SJ, Tsang PS, Diaz TM, Wei BY, Stetler-Stevenson WG.

Lab Invest. 2010 Mar;90(3):374-82. doi: 10.1038/labinvest.2009.136. Epub 2010 Jan 18.

33.

The prognostic value of TIMP-1 in multiple myeloma.

Guedez L, Stetler-Stevenson WG.

Leuk Res. 2010 May;34(5):576-7. doi: 10.1016/j.leukres.2009.10.005. Epub 2009 Oct 29. No abstract available.

34.

Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.

Sun J, Stetler-Stevenson WG.

J Mol Signal. 2009 Jul 23;4:4. doi: 10.1186/1750-2187-4-4.

35.

Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.

Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.

Cancer Sci. 2009 Sep;100(9):1748-56. doi: 10.1111/j.1349-7006.2009.01244.x. Epub 2009 Jun 17.

36.

Matrix metalloproteinases.

Birkedal-Hansen H, Yamada S, Windsor J, Pollard AH, Lyons G, Stetler-Stevenson W, Birkedal-Hansen B.

Curr Protoc Cell Biol. 2008 Sep;Chapter 10:Unit 10.8. doi: 10.1002/0471143030.cb1008s40.

PMID:
18819088
37.

TIMP-2 disrupts FGF-2-induced downstream signaling pathways.

Seo DW, Kim SH, Eom SH, Yoon HJ, Cho YR, Kim PH, Kim YK, Han JW, Diaz T, Wei BY, Stetler-Stevenson WG.

Microvasc Res. 2008 Nov;76(3):145-51. doi: 10.1016/j.mvr.2008.07.003. Epub 2008 Jul 29.

38.

Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.

Stetler-Stevenson WG.

Sci Signal. 2008 Jul 8;1(27):re6. doi: 10.1126/scisignal.127re6. Review.

39.

TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.

Kim YS, Seo DW, Kong SK, Lee JH, Lee ES, Stetler-Stevenson M, Stetler-Stevenson WG.

Cancer Lett. 2008 Sep 28;269(1):37-45. doi: 10.1016/j.canlet.2008.04.020. Epub 2008 May 23.

40.

Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance.

Haviernik P, Diaz MT, Haviernikova E, Tse W, Stetler-Stevenson WG, Bunting KD.

Blood Cells Mol Dis. 2008 Sep-Oct;41(2):179-87. doi: 10.1016/j.bcmd.2008.03.005. Epub 2008 May 19.

41.

TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells.

Lee H, Lim C, Lee J, Kim N, Bang S, Lee H, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J.

J Cell Biochem. 2008 Jun 1;104(3):1065-74. doi: 10.1002/jcb.21692.

PMID:
18300271
42.

Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness.

Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M.

J Clin Endocrinol Metab. 2008 May;93(5):1625-33. doi: 10.1210/jc.2007-1283. Epub 2008 Feb 19.

PMID:
18285421
43.

Matrix metalloproteinases.

Birkedal-Hansen H, Yamada S, Windsor J, Poulsen AH, Lyons G, Stetler-Stevenson W, Birkedal-Hansen B.

Curr Protoc Cell Biol. 2003 Feb;Chapter 10:Unit 10.8. doi: 10.1002/0471143030.cb1008s17.

PMID:
18228416
44.
45.

Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.

Cancer Res. 2007 Aug 1;67(15):7238-46.

46.

TIMP-2 promotes cell spreading and adhesion via upregulation of Rap1 signaling.

Chang H, Lee J, Poo H, Noda M, Diaz T, Wei B, Stetler-Stevenson WG, Oh J.

Biochem Biophys Res Commun. 2006 Jul 7;345(3):1201-6. Epub 2006 May 15.

PMID:
16716258
47.

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.

Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T.

J Exp Med. 2006 May 15;203(5):1235-47. Epub 2006 Apr 24.

48.

Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2.

Elliot S, Catanuto P, Stetler-Stevenson W, Cousins SW.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1696-702.

49.

TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118.

Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG.

Oncogene. 2006 Jul 13;25(30):4230-4. Epub 2006 Feb 20.

50.

Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells.

Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG.

J Biol Chem. 2006 Feb 10;281(6):3711-21. Epub 2005 Dec 2.

Supplemental Content

Loading ...
Support Center